As the role of major post induction treatn~nt alternatives for AML re~ained controversial we started a trial at 30 institutions in 1981. 331 of 568 (58%) adult pts with AML achieved ccslolete remission (CR) by a 9 day combination of thioguanine, ARA-C and daunorubicin (TAD9). 221 responders were eligable by protocol criteria. Randomization was different for the two study parts; A: consolidation by TAD9 with vs without maintenance by CALGB type monthly che[notherapy. B: maintenance with vs without ~otherapy using neuraminidase treated allogeneic blasts. In part A prolongation of CR by consequent post induction chemDtherapy is clearly shown (p=0.001).
(Supported by BMFT 01ZP0123). Alternating chemotherapy was evaluated in pts with SCLC. In study I 306 pts were randomized to receive regime A consisting of 8 cycles of CAV (= cyclophosphamide Ig/m2; adriamycin 50mg/m2; vincristine 2mg; d I) or regime B consisting of 3 cycles (1,3,5) of VPIV (= VPI6 80mg/m 2 d 1-3; ifosfamiae 1500mg/m 2 d 1-5; vindesine 3mg/m 2 a I) alternating with 3 cycles (2,4,6) of PAV (= cis-platinum 90mg/m2; adriamycin 60 mg/m2; vincristine 2mg day; d i) in 3 week intervals followed by one cycle of CMCC (= cyclophosphamide ig/m 2 d 1,22; methotrexate 15mg/m 2 d 1,4,8, Ii; CCNU 100mg/m 2 d I). Responders received a prophylactic cranial irradiation after 3 cycles and chest irradiation after 8 cycles. Overall best response was 59% vs. 70%, complete remission rate was 21% vs. 36%, median survival was 9.8 vs. 11.3 months, and 2-year survival was 6% vs. 9%, all in favor of arm B. Predominately response was seen after cycle i. 10/42 (24%) non-responders in A and 17/31 (55%) non-responders in B profit from the continuous application of the same regime. Switching to the other treatment regime was successful in 29/44 (66%) pts in A and in 8/20 (40%) pts in B. Thus, immediate switch to a "non-cross-resistant"second line therapy may improve the outcome of non-responders. Therefore we designed study II comparing fixed alternating treatment with a response-orientated individualized treatment. In a pilot study on 144 pts the efficacy and cross-resistance to CAV of IVP (arm A, = ifosfamide 1500mg/m 2 d 1-5; VPI6 120mg/m 2 d 3-5), and PVP (arm B, = cls-platinnm 80mg/m 2 d I; VPl6 150mg/e 2 d 3-5) was tested. Non-responders switched to the standard CAV regime. Overall response and complete remission rate were similar in both treatment arms. Median survival was 9.4 vs. 11.6 months in favor of B. PVP treatment showed s higher degree of side effects (WHO criteria). 58 pts switched to the second line therapy of CAV. 13/30 (43%) pts of A and 7/28 (25%) pts of ~ experienced a secondary response to CAV. Thus, we used IVP as front line regime in study II. Regime A consists of alternating treatment with CAV and IVP, regime e consists of sequential IVP treatment followed by CAV at the time IVP fails to work. 130 pts entered the study until now. Overall response rate was similar in both arms (89% (Blood, 49, 379, 1977) . Both assessments correlated wet1. 64% of all patients had complete (>75% tumour mass reduction) or partial remissions (>25% tumour mass reduction), 19% showed no change, end 17% progressed during induction therapy. The results were equal in both treatment groups, showing no advantage for the multi-drug regimen. Patients in remission were randomized in groups without or with maintenance therapy consisting of prior chemotherapy cycles q 8 weeks. Patients without maintenance therapy relapsed significantly earlier than patients receiving maintenance therapy (after 10 months 10% of the maintenance group versus 50% of the no maintenance group). 7/11 relapse patients of the no maintenance group went into remission again after reinduction treatment (6 cycles of their previous induction therapy scheme). Therefore in this qroup the influence of early relapse on survival remains open to date. Most therapeutic strategies in small cell lung cancer stage "limited disease", combine chemotherapy and radiation to the primary. While improvement of median survival by chemotherapy is unquestioned, the addition of chest irradiation is still controversal and optimal timing and dosage have not been determined. Therefore, we initiated a randomized phase III study in stage "limited disease" with 3 arms combining 6 cycles of ACO with either no radiation to the primary (A), or 30 Gy (B) and 50 Gy (C) after the third cycle, respectively. All patients obtain a prophylactic cranial irradiation of 30 Gy after the third cycle. If this therapeutic regimen fails, chemotherapy is changed to cis-platinum plus etoposid. Until October 1985 64 patients with small cell cancer stage "limited disease" have been entered into the study, 62 are evaluable. 11 of the 62 patients were females. 6 patients were non-smokers. 20 patients had weight loss, 44 cough and 10 fever at diagnosis. 21 patients were of age 33 to 49, 22 of age 50 to 59 and 19 of age 60 to 70 years, respectively. The distribution of sex, age and symptoms was well balanced between the 3 arms. In arm A 8/17 patients died, in arm B 5/24 and in arm C 12/21. Median survival in arm A is 12.2 months, in arm B 11.5 months and in arm C 15.9 months, respectively. The difference is statistically not significant and no conclusions can be drawn from the preliminary data at present. 
